Researchers found that performing National Comprehensive Cancer Network guideline recommendations to detect early signs of myeloma reduces hospital costs.
ASH Annual Meeting
A poster at ASH 2017 found that Neupogen, Granix, and Zarxio were substantially less expensive than Neulesta for an average chemotherapy treatment cycle.
A study presented at ASH highlighted the benefits of a pharmacist-physician professional team in delivering outpatient cancer care.
Research at ASH 2017 found that switching lymphoma patients to a biosimilar could free up budget money in order to cover the cost of expensive cancer therapies.
A study at the ASH 2017 Annual Meeting measured the cost-effectiveness of Xarelto compared to the cost-effectiveness of aspirin only.